Cyrus Mozayeni, Vedere Bio CEO
Months after Novartis buyout, the old Vedere Bio team is back at it with a new pipeline and a fresh $77M
What do you do when Novartis plunks down $150 million to buy your startup before you even hit the clinic? If you’re Cyrus Mozayeni, you …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
